February 14, 2018 / 4:22 AM / in 8 months

BRIEF-Shanghai Fosun Pharmaceutical Group unit gets sole license on research of anticarcinogen in China

Feb 14 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd :

* Says its unit signs License and Option Agreement with U.S. company Galaxy Biotech, LLC, to get sole license on research and development of monoclonal antibody for anticarcinogen new drug in China

Source text in Chinese: goo.gl/JmZvq6

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below